European Pharmaceutical Review

NOVEMBER 7, 2024

percent between 2025 and 2030. Sartorius AG and Merck KGaA, Single-use technology propelling upstream bioprocessing market expansion The post Single-use bioreactor market to witness favourable expansion to 2030 appeared first on European Pharmaceutical Review.

Compounding 52

Compounding Vaccines 52

Hospital Pharmacy Europe

JANUARY 25, 2024

The vision sets out a multifaceted approach under five strategic pillars to help to ensure consultant pharmacists are an integral part of the pharmacy and wider healthcare team in all sectors of the UK by 2030. The post Vision for consultant pharmacists by 2030 unveiled by RPS appeared first on Hospital Pharmacy Europe.

Documentation 98

Documentation Hospitals 98

European Pharmaceutical Review

JULY 18, 2023

billion by 2030. Digitalisation to boost quality management systems market The post QMS market to value nearly $4b by 2030 appeared first on European Pharmaceutical Review. According to the research, the pharmaceutical quality management systems market is projected to reach $3.97

Documentation 98

Documentation Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

AUGUST 21, 2023

billion by 2030 and grow at a CAGR of 3.84 percent from 2023 to 2030. billion by 2030 appeared first on European Pharmaceutical Review. According to a market report , the global RNA therapy clinical trials market is anticipated to reach $3.5

Vaccines 98

Vaccines 98

European Pharmaceutical Review

OCTOBER 18, 2022

billion by 2030, according to a market report. The Asia Pacific region is expected to register the fastest growth from 2022-2030 due to the presence of the large HPAPI manufacturers in China. billion by 2030 appeared first on European Pharmaceutical Review. billion in 2022 to $14.65

Dosage 105

Dosage Vaccines 105

Fierce Pharma

JANUARY 10, 2024

In AZ's push to reach industry-leading growth by 2030, confidence is key, chief financial officer Aradhana Sarin said at the J.P. With a late-stage pipeline spanning more than 120 clinical trials and a firm grasp of five major disease areas, AstraZeneca appears confident heading into 2024. | Morgan Healthcare Conference.

Labelling 103

Labelling 103

Fierce Pharma

NOVEMBER 14, 2023

Failure of the Imfinzi-concurrent-chemoradiotherapy regimen deals a blow to AZ’s goal to target more than half of lung cancer patients by 2030. . | One study in AstraZeneca’s elaborate R&D plan for lung cancer has reached a dead end.

89

89

Fierce Pharma

OCTOBER 6, 2023

With the new real estate, Lotte plans to build out three separate bio plants by 2030. . | Lotte this week unveiled a land purchase agreement with the Incheon Free Economic Zone Authority in Incheon, Korea.

100

100

Fierce Pharma

JUNE 28, 2023

With that new investment, the company is raising its commitment to plant and nurture 200 million trees across six continents by 2030—the same year AstraZeneca aims to halve its environmental footprint across its entire value chain.

91

91

Fierce Pharma

JUNE 17, 2024

As part of Vision 2030, argenx will touch on its continuing commitment to tackle severe autoimmune diseases with Vyvgart. As argenx homes in on the next indication for its pipeline-in-a-product Vyvgart (efgartigimod), the company is preparing for the next leg of its commercial journey. |

52

52

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8

Generic Medicine 98

Generic Medicine Chemotherapy 98

The Guardian - Pharmaceutical Industry

MAY 21, 2024

As the company prepared to present its growth plans to shareholders at its labs and corporate headquarters in Cambridge, it said many of the 20 new drugs will have the potential to generate more than $5bn in annual revenues at their peak.

53

53

Fierce Pharma

JUNE 29, 2023

By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday. While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. |

Vaccines 85

Vaccines Immunization 85

pharmaphorum

OCTOBER 26, 2020

CRA’s Life Sciences Practice recently conducted an analysis of the barriers that currently limit reimbursement for many preventive care services and how the evolution of healthcare systems and preventive care offerings could change the demand and uptake of preventive care by 2030. How could payer views change by 2030?

Vaccines 130

Vaccines 130

European Pharmaceutical Review

AUGUST 15, 2023

billion by 2030, according to a report from Data Bridge Market Research. The sublingual films segment is projected to grow at the highest rate during the forecast period 2023-2030. by 2030 appeared first on European Pharmaceutical Review. The global buccal drug delivery market is projected to grow from $3.38

Dosage 52

Dosage Compounding 52

European Pharmaceutical Review

AUGUST 17, 2022

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. According to a recent report , the global formulation development outsourcing market size should grow to $61.4

Compounding 96

Compounding Pharmaceutical Companies Pharmaceutical Companies 96

Fierce Pharma

FEBRUARY 9, 2023

Now, it plans 15 drug launches by 2030 aliu Thu, 02/09/2023 - 10:00 AstraZeneca met CEO Pascal Soriot's $40B revenue goal early.

96

96

European Pharmaceutical Review

OCTOBER 7, 2022

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 billion by 2030 appeared first on European Pharmaceutical Review. A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Leading companies in the oral solid dosage market are Catalent, Inc.,

Dosage 98

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 98

Fierce Pharma

JANUARY 24, 2023

Bayer’s oncology business looks to collect $10B in sales by 2030, exec says zbecker Tue, 01/24/2023 - 09:14

81

81

Fierce Pharma

OCTOBER 2, 2023

With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts kdunleavy Mon, 10/02/2023 - 15:19

63

63

Pharmaceutical Technology

DECEMBER 16, 2022

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.

Compounding 59

Compounding Labelling 59

Fierce Pharma

OCTOBER 16, 2024

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively pushing the earliest generic entry out to 2030. |

100

100

Fierce Pharma

NOVEMBER 1, 2024

Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’ Vyvgart is already making headway in the rare disease space, just one of the long-term growt | So far, argenx's Vyvgart has reached 300 patients with chronic inflammatory demyelinating polyneuropathy (CIDP) after securing an FDA approval in (..)

FDA 98

FDA 98

Fierce Pharma

NOVEMBER 12, 2024

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper collection of patient data that have implicated senior executives, AstraZeneca CE | Despite China’s investigations that have implicated senior executives, AstraZeneca CEO Pascal Soriot argued that the company did not lose oversight and (..)

Insurance 119

Insurance 119

Drug Topics

AUGUST 22, 2024

Access inequities are preventing the US-affiliated Pacific Island (USAPI) jurisdictions from meeting the WHO 2030 goal of 90% human papillomavirus (HPV) vaccination series completion coverage.

Vaccines 112

Vaccines 112

Fierce Healthcare

NOVEMBER 11, 2024

Accountable care organizations in the ACO Reach program can claim credit for saving the Centers for Medicare & Medicaid Services (CMS) hundreds of millions of dollars | CMS released favorable savings results for ACO REACH Model participants, as industry group NAACOS begins to push for the program's extension through 2030.

108

108

Pharma Mirror

OCTOBER 28, 2021

Amsterdam, The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The post CPhI Annual Report 2021: Short term reshoring the catalyst for longer term manufacturing innovations by 2030 appeared first on Pharma Mirror Magazine.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

JUNE 14, 2023

The recommendations to combat AMR propose that there should be a 20% reduction in the total human consumption of antibiotics by 2030 alongside an even larger pushback against their use in animals, per the 13 June announcement.

Long-Term Care Facilities 52

Long-Term Care Facilities Documentation Hospitals 52

Fierce Pharma

OCTOBER 31, 2024

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional fright surrounding another staple product took the spotlight during the co | Despite the China growth woes, Merck is still confident it can achieve its $11 billion sales goal for the HPV vaccine by 2030.

Vaccines 110

Vaccines 110

Roots Analysis

FEBRUARY 26, 2024

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research You may also be interested in the following titles: Continuous Manufacturing (Small Molecules and Biologics) Market Subcutaneous Biologics, Technologies and Drug Delivery Systems Market Antibody Discovery Services and Platforms Market Our Social Media Platform Web: (..)

52

52

STAT

OCTOBER 21, 2024

Scientific experts tasked with advising federal officials drafting the 2025-2030 Dietary Guidelines for Americans said the data were far too limited to draw conclusions. If you were hoping to see where ultra-processed foods might fit in the next Dietary Guidelines for Americans, hold that thought.

144

144

pharmaphorum

DECEMBER 7, 2023

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on earlier predictions.

103

103

Pharmaceutical Technology

SEPTEMBER 18, 2024

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData analysis.

Labelling 98

Labelling FDA 98

The Guardian - Pharmaceutical Industry

OCTOBER 16, 2022

ahin and Özlem Türeci say mRNA Covid vaccine technology could be repurposed to help destroy cancer cells Vaccines that target cancer could be available before the end of the decade, according to the husband and wife team behind one of the most successful Covid vaccines of the pandemic.

Vaccines 102

Vaccines 102

Fierce Pharma

NOVEMBER 26, 2024

| Takeda is focused on curbing dengue with innovative solutions and public-private partnerships to achieve the WHO’s goal of zero dengue deaths by 2030.

52

52

Outsourcing Pharma

SEPTEMBER 12, 2023

The increasing prevalence of chronic diseases could see the market for active pharmaceutical ingredients (APIs) growing by 7.5% per year, says a report by Prophecy Market Insights.

84

84

Pharma Mirror

NOVEMBER 23, 2021

The post AI in Pharma and Biotech Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2030 appeared first on Pharma Mirror Magazine.

Patient Care 52

Patient Care 52